Suppr超能文献

单体型相合造血干细胞移植治疗 6 号染色体单体性淋巴瘤(HLA 区域杂合性缺失)——谁应该作为供者?

Haploidentical hematopoietic stem cell transplantation for lymphoma with monosomy of chromosome 6 (loss of heterozygosity in the HLA region)--who should be a donor?

机构信息

Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.

出版信息

Transpl Immunol. 2012 Dec;27(4):162-5. doi: 10.1016/j.trim.2012.09.002. Epub 2012 Sep 19.

Abstract

Hematopoietic stem cell transplantation (HSCT) from an HLA haploidentical family donor is an option for patients who do not have a full HLA matched donor and lack the time to find an unrelated one [1,2]. Furthermore, it may facilitate a powerful graft versus leukemia/lymphoma (GVL) effect to help combat hematological malignancies by directly targeting the mismatched HLA expressed on leukemia/lymphoma cells [3]. On the contrary, leukemia/lymphoma cells escape from the surveillance of the donor-derived GVL effect by losing the target HLA (mismatched HLA in GVH direction). This mechanism has been called loss of heterozygosity (LOH) in the HLA gene region on chromosome 6 [4,5]. Taking the above into account, in this case report, we present a case of lymphoma with monosomy 6, which means natural LOH of HLA, and suggest that selection of a haploidentical family donor matched with the missing HLA haplotype seems to be very effective.

摘要

造血干细胞移植(HSCT)来自 HLA 半相合家族供者,是那些没有完全 HLA 匹配供者且缺乏寻找无关供者时间的患者的选择[1,2]。此外,它可以通过直接针对白血病/淋巴瘤细胞上表达的不合 HLA 来促进强大的移植物抗白血病/淋巴瘤(GVL)效应,从而帮助对抗血液系统恶性肿瘤[3]。相反,白血病/淋巴瘤细胞通过失去靶 HLA(GVH 方向的不合 HLA)而逃避供体来源的 GVL 效应的监测。这种机制在 HLA 基因区域的染色体 6 上被称为杂合性丢失(LOH)[4,5]。考虑到这一点,在本病例报告中,我们报告了一例淋巴瘤伴单体 6,这意味着 HLA 的自然 LOH,并且表明选择与缺失 HLA 单倍型匹配的半相合家族供者似乎非常有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验